Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
新辅助卡瑞利珠单抗（一种抗PD-1抗体）联合化疗或阿帕替尼（一种VEGFR-2抑制剂）治疗初始不可切除的II-III期非小细胞肺癌：一项多中心、双臂、II期探索性研究
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-024-01861-w
Xia, Haoran; Zhang, Han; Ruan, Zheng; Zhang, Huibiao; Sun, Liangdong; Chen, Hezhong; Zhou, Yongxin; Zhang, Lele; Bian, Dongliang; Zhu, Xinsheng; Zhang, Jing; Sun, Fenghuan; Yu, Huansha; Song, Nan; Liu, Xiaogang; Zhu, Yuming; Zhang, Haiping; He, Wenxin; Chen, Jian; Yang, Jie; Chen, Guohan; Xie, Shiliang; Tang, Dongfang; Zhang, Xiaomiao; Duan, Liang; Zhao, Deping; Li, Qinchuan; Zhang, Peng; Jiang, Gening
肺癌
肿瘤
肿瘤免疫
细胞生物学
EGF
EGFR
VEGF
PD-1
